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Background: Recurrent aphthous stomatitis (RAS) is a common condition that affects approximately 20% of the 
general population. The ulcers can interfere with speech and eating and cause significant pain and discomfort. This 
study aimed to evaluate the efficacy of Amlexanox and Adcortyl in the treatment of aphthous ulcers.
Material and Methods: In this randomized double blind clinical trial with sequential patient entry, a total of 40 pa-
tients who presented with aphthous ulcers were included. Patients were received Amlexanox or Adcortyl four times 
daily for 7 days. Patients were evaluated for pain, lesion size, and tingling at one day, three days, five days and se-
ven days follow-ups. The treatment effects were then evaluated using the Wilcoxon–Mann–Whitney (WMW) test. 
Values of p<0.05 were considered significant.
Results: No significant differences in pain score, tingling and lesion size were observed on similar days between 
Amlexanox and Adcortyl groups. In both groups, reduction in the assessed variables was significant between days 
1-3, 3-5, and 5-7 (p < 0.001).
Conclusions: This study indicated that Amlexanox as well as Adcortyl was effective in relieving pain and reducing 
the lesion size during the treatment of aphthous ulcers.
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Introduction
Recurrent aphthous stomatitis (RAS) is a common con-
dition that characterized by recurrent attacks of single or 
multiple small pin-head ulcers covering by fibrin on the 
mucous of mouth and rarely genital region that affects 
approximately 5-25% of the general population (1).
This condition is associated with recurrent bouts of sin-
gle or multiple rounded, shallow and painful lesions su-
rrounded by inflammation in oral mucosa that may occur 
at intervals of few days to a few months. These lesions 
most commonly occur on the non-keratinized mobile 
oral mucosal surfaces and heal within 10-14 days (2,3).
Studies have introduced different factors that predispose 
to RAS, such as systemic diseases, genetic predisposi-
tion, immune disorders, drugs, stress, trauma, foods, hor-
monal changes, nutrients deficiency, and so on. Howe-
ver, the etiology of RAS still remains unknown (4-6). 
Pain is the obvious characteristic of the aphthous ulcera-
tions causing difficulty while chewing, swallowing, and 
speaking (2). So far, a number of different treatment op-
tions have been introduced such as steroids, analgesics, 
topical anesthetics agents, antiseptics and anti-inflam-
matory agents, sucralfate suspension, tetracycline sus-
pension, silver nitrate cauterization, laser ablation and 
traditional and home complementary remedies. Because 
of the broad spectrum of side effects following admi-
nistration of some agents including steroids, the topical 
drug forms such as pasts are preferred. However, there is 
no definitive curative treatment for RAS (7-9). 
In this regard, some studies have been conducted on the 
use of Amlexanox as an anti-inflammatory antiallergic 
immunomodulator drug to treat recurrent aphthous ul-
cers (10-12). According to our knowledge, no study has 
been carried out in Iran on the effects of either Amlexa-
nox or Adcortyl in the treatment of aphthous ulcers. 
On the other hand, the identification of the relation bet-
ween genotype and drug response, including both the 
therapeutic effect and side effect profile, is expected 
to deeply affect medical practice (13). So, the purpose 
of the present study is to evaluate the effectiveness of 
Amlexanox and Adcortyl for the treatment of recurrent 
aphthous ulcers in Iran.
Material and Methods 
This double-blinded randomized clinical trial was 
approved by the research ethics committee at Shahed 
University of Medical Sciences, Tehran, Iran. The in-
clusion criteria for patients bearing recurrent aphthous 
ulcers were as follows: age between 18 and 40 years 
old and above, having minor aphthous ulcer not more 
than 2 days, not taking any analgesic, antiseptic or sys-
temic or topical corticosteroid therapy prior to the study. 
Exclusion criteria were patients with systemic diseases 
(ulcerative colitis, Crohn’s disease, and Behcet disease), 
smoking, pregnancy or lactating, undergoing therapy for 
aphthous ulcers, wearing a denture, estimation of poor 
cooperation during the study. Each patient was informed 
about the procedure and his/her informed consent was 
obtained.
Forty patients attending Shahed Dental School and Firo-
ozgar hospital were randomized into two groups equa-
lly. In group 1, Adcortyl 0.1% was administered, while 
the group 2 received Amlexanox. The patients used 5% 
Amlexanox four times daily for 7 days. The application 
of drugs was instructed to the subjects and they were 
asked to use it after every meal and before sleep. The 
patients were also asked to refrain from using any other 
medications. The treatment duration was 7 days and pa-
tients were asked to evaluate the severity of pain and 
tingling by using a 10-point visual analog scale (VAS: 
0-10; 0=no pain or tingling and 10= worst possible pain 
or tingling). The scores were assessed at one day, three 
days, five days and seven days follow-ups. The area 
(mm2) of ulceration was measured by a caliper. The cli-
nician who performed assessments and patients were 
unaware of the treatment.
-Statistical analysis
The collected data were analyzed by SPSS version 
17.0. Results were compared using t-test, Wilcoxon and 
ANOVA with turkey’s as post hoc tests. The statistically 
significant level was accepted as a p value < 0.05.
Results
The study group comprised of 18 men and 22 women 
with an average age of 36.2±3.36 years. The groups 
were similar in terms of age, gender, referral day, le-
sion size, pain and tingling at admission. No side effect, 
which could restrict the progression of treatment, was 
reported by the cases who applied the study drugs and all 
participants finished the period of the study. 
The results revealed that in both of the groups, the pain 
score was significantly reduced at subsequent follow-
ups at 1st, 3d, 5th and 7th days (p<0.001). At 7 days, 
none of the patients in both groups experienced pain. 
There were no significant differences between Adcortyl 
and Amlexanox in terms of their efficacy on pain relieve 
observed in the present study (Fig. 1). 
Moreover, both of the drugs led to remarkable reduc-
tion in tingling score at subsequent follow-ups at 1st, 3d, 
5th and 7th days (P˂0.001). Interestingly, despite the 
participants in Amlexanox group, the patients that used 
Adcortyl didn’t report any tingling at the 7th day (Fig. 
2 left). However, there were no significant differences 
between Adcortyl and Amlexanox in terms of their effi-
cacy on tingling relieve observed in the present study 
(Fig. 2).
Based on the results of Wilcoxon test, lesion size in each 
of the groups was significantly decreased at subsequent 
follow-ups at 1st, 3d, 5th and 7th days (p<0.001). Howe-
ver, there were no significant differences between the 
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Fig. 1. The mean value of pain scores on days 1, 3, 5 and 7 of the treatment in Amlexanox and Adcortyl 
groups. There were statistically significant differences between the studied time intervals in both of 
the groups (p < 0.001) (left). Trend of pain intensity based on VAS on days 1, 3, 5 and 7 of the treat-
ment in both of the groups. There was no significant difference between the Amlexanox and Adcortyl 
group for pain reduction (right). 
Fig. 2. The mean value of tingling scores on days 1, 3, 5 and 7 of the treatment in Amlexanox and 
Adcortyl groups. There were statistically significant differences between the studied time intervals in 
both of the groups (p < 0.001) (left). Trend of tingling intensity based on VAS on days 1, 3, 5 and 7 of 
the treatment in both of the groups. There was no significant difference between the Amlexanox and 
Adcortyl groups for tingling reduction (right). 
Fig. 3. The mean ulcer size (mm2) on days 1, 3, 5 and 7 of the treatment in Amlexanox and Adcortyl 
groups. There were statistically significant differences between the studied time intervals in both of 
the groups (p < 0.001) (left). Trend of ulcer size on days 1, 3, 5 and 7 of the treatment in both of the 
groups. There was no significant difference between the Amlexanox and Adcortyl groups for reduc-
tion of ulcer size (right). 
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two groups in terms of lesion size at 1st, 3d, 5th and 7th 
day follow-ups (Fig. 3 right). Despite the Amlexanox 
group, the score for lesion size in Adcortyl group was 
zero at the 7th day  (Fig. 3).
Discussion
RAS is characterized by remarkably painful ulcers causing 
difficulty in eating, swallowing, and speaking. The main 
goal of treatment modality is to decrease pain, healing time, 
number and size of the ulcer (14). The present study showed 
that both Amlexanox and Adcortyl decreased pain intensity, 
tingling and size of ulcers within 7 days. Moreover, there 
were no significant differences between the groups.
Consistent with the present results, Liu J et al. (10) have 
reported that Amlexanox significantly reduces the pain 
severity of aphthous stomatitis. Khandwala A et al. (15) 
stated that in comparison to vehicle-treated subjects, the 
subjects treated with 5% Amlexanox expressed greater 
reduction in ulcer size and pain on days 3 to 5. A cli-
nical study had compared the recurrence rate between 
the Amlexanox and control group and proved that 5% of 
Amlexanox oral paste is clinically beneficial in reducing 
the pain, erythema, exudation and size of the ulcer over 
a period of 6 days (16). Murray B et al. (11) concluded 
that treatment with 5% Amlexanox paste at the onset of 
prodromal recurrent minor aphthous ulceration symp-
toms can prevent progression to ulcer development and 
significantly reduced symptoms if ulcers do develop. 
In a study, Natah SS et al. (17) concluded that the best 
treatment for aphthous minor might be 5% Amlexanox 
with multiple actions including preventing recurrence, 
decreasing healing time and pain reduction. It’s espe-
cially true when it is used from the prodromal stage till 
healing completes for four times a day. 
Amlexanox is currently the only clinically proven 
product approved by the US FDA for the treatment of 
aphthous ulcers (18). Its mechanism of action is not well 
determined, but Amlexanox have anti-allergic and anti-
inflammatory properties. These activities may be impor-
tant in accelerating the healing process (19). 
Due to the side effects and adverse events of systemic 
drugs, local drug delivery systems have been widely de-
veloped regarding the treatment of oral lesions (20). This 
may be an advantage of the paste form of Amlexanox. 
However, it has been shown that most of the systemic 
absorption of Amlexanox probably results from the gas-
trointestinal track after swallowing the 5% Amlexanox 
paste rather than directly through the ulcer. On the other 
hand, in the safety and efficacy studies of 5% Amlexanox 
paste for the treatment of aphthous ulcers, the incidence 
of adverse events potentially related to 5% Amlexanox 
paste was very low and similar to the vehicle (21). On 
the other hand, the long -term use of Adcortyl has been 
reported to be associated with the development of local 
candida infection (22).
We had limitations in this study in regard to relatively 
small sample size and duration of the study period, 
which require future randomized controlled trial studies 
in larger populations. Since aphthous has recurrent cha-
racteristics, so the importance of long-term treatment 
program may be beneficial. 
In conclusion, it seems that both Amlexanox and Adcor-
tyl are effective treatment options for RAS. However, 
there were no significant difference between Amlexanox 
and Adcortyl for treatment of RAS regarding pain, tin-
gling and ulcer size reduction. 
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